scholarly journals The ring size of monocyclic ET‐1 controls selectivity and signaling efficiency at both endothelin receptor subtypes

2021 ◽  
Author(s):  
Philipp Wolf ◽  
Annette G. Beck‐Sickinger
1995 ◽  
Vol 26 ◽  
pp. S470-472
Author(s):  
Berthold Hocher ◽  
Peter Rohmeiss ◽  
Rüdiger Zart ◽  
Fritz Diekmann ◽  
Volker Vogt ◽  
...  

1999 ◽  
Vol 20 (4) ◽  
pp. 620-630 ◽  
Author(s):  
Sanae Soma ◽  
Hideki Takahashi ◽  
Masashi Muramatsu ◽  
Masahiko Oka ◽  
Yoshinosuke Fukuchi

1996 ◽  
Vol 23 (6-7) ◽  
pp. 524-531 ◽  
Author(s):  
Rachael Dean ◽  
Jialong Zhuo ◽  
Daine Alcorn ◽  
David Casley ◽  
Frederick AO Mendelsohn

1992 ◽  
Vol 182 (1) ◽  
pp. 144-150 ◽  
Author(s):  
Kyoko Nakamichi ◽  
Masaki Ihara ◽  
Masahiko Kobayashi ◽  
Toshihiko Saeki ◽  
Kiyofumi Ishikawa ◽  
...  

1995 ◽  
Vol 26 ◽  
pp. S163-168 ◽  
Author(s):  
Stephen A. Douglas ◽  
George R. Beck ◽  
John D. Elliott ◽  
Eliot H. Ohlstein

1994 ◽  
Vol 72 (11) ◽  
pp. 1469-1471 ◽  
Author(s):  
Suzanne Moreland

The endothelins are a family of potent vasoconstrictors, some of which also have vasodilatory activity. In many diseases associated with tissue hypoxia or ischemia and in diseases in which vasoconstriction plays a role, the circulating levels of endothelin are higher than in healthy, control subjects. These findings stimulated research aimed at discovering endothelin receptor antagonists. This review focuses on the binding potency and vascular activity of these new peptide and nonpeptide endothelin receptor antagonists.Key words: endothelin, endothelin receptor subtypes, vascular smooth muscle, endothelin receptor antagonist.


Sign in / Sign up

Export Citation Format

Share Document